Bouse Malkots
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bouse Malkots has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Emmanouil Panagiotopoulos
Department of Hematology, Democritus University of Thrace Medical School, 68 100 Alexandroupolis, Greece
2 shared publications - Emmanouil Spanoudakis
Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece
2 shared publications - Iliana Stamatiou
Department of Haematology University Hospital of Alexandroupolis, Democritus University of Thrace Alexandroupolis Greece
2 shared publications - Ioannis Kotsianidis
Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
2 shared publications - Konstantinos Liapis
Department of Haematology Democritus University of Thrace Medical School Alexandroupolis Greece
2 shared publications - Lydia Inglezou
Department of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, 681 00 Alexandroupoli, Greece
2 shared publications
Latest Publications
- Open Access
Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta‐analysis
The authors performed a systematic review and meta‐analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals with MDS have a high rate of cardiovascular disease that is 6.2 times greater than that in the general population. A remarkably high prevalence of heart failure (between 10.4% and 18.6%) was observed, indicating that heart failure is a major issue that warrants urgent attention in MDS. The prevalence of chronic kidney disease, chronic liver disease, and solid tumors was also higher in patients with MDS. The results of this analysis indicate a much higher prevalence of multimorbidity in patients who have MDS compared with the general population (79.1% vs. 63.4%; p < .0001). Furthermore, the data demonstrate that the association between MDS and noncommunicable diseases remains strong in both high‐income and low‐income regions, the comorbidity burden increases with higher scores on the revised International Prognostic Scoring System, patients with multimorbidity are twice as likely to die as those without multimorbidity, and a high burden of comorbidities emerges as a common problem in MDS, occurring in 35% of patients. These findings suggest that a focus on multimorbidity and a holistic, multidisciplinary, and patient‐centered approach to address the challenge of common chronic diseases could significantly improve outcomes for patients with MDS.
Open AccessExcess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta‐analysis
The authors performed a systematic review and meta‐analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals with MDS have a high rate of cardiovascular disease that is 6.2 times greater than that in the general population. A remarkably high prevalence of heart failure (between 10.4% and 18.6%) was observed, indicating that heart failure is a major issue that warrants urgent attention in MDS. The prevalence of chronic kidney disease, chronic liver disease, and solid tumors was also higher in patients with MDS. The results of this analysis indicate a much higher prevalence of multimorbidity in patients who have MDS compared with the general population (79.1% vs. 63.4%; p < .0001). Furthermore, the data demonstrate that the association between MDS and noncommunicable diseases remains strong in both high‐income and low‐income regions, the comorbidity burden increases with higher scores on the revised International Prognostic Scoring System, patients with multimorbidity are twice as likely to die as those without multimorbidity, and a high burden of comorbidities emerges as a common problem in MDS, occurring in 35% of patients. These findings suggest that a focus on multimorbidity and a holistic, multidisciplinary, and patient‐centered approach to address the challenge of common chronic diseases could significantly improve outcomes for patients with MDS.
- Open Access
- 7 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3571
The Role of Gut Microbiota in Acute Myeloid Leukemia
Gut microbiota plays a crucial role in regulating immune system function and shaping immunological responses to pathogens capable of causing infections. Alterations in the composition of the intestinal microbiome are associated with immune system dysfunction and increased susceptibility to infections. Patients with acute myeloid leukemia (AML) are highly susceptible to infections due to immune system deregulation caused by the disease itself, as well as chemotherapy-induced bone marrow aplasia. In these patients, gut microbiota dysbiosis and reduced microbial diversity (i.e., imbalances in the composition and function of intestinal microbes) result from multiple factors, including the underlying disease, neutropenia, dietary factors, use of antibiotics, chemotherapy regimens and prolonged hospitalization. Chemotherapy, for instance, induces damage to the intestinal mucosa and disrupts the epithelial barrier, resulting in deregulation of the intestinal microbiome. Previous studies have reported alterations in the human intestinal microbiome in patients with AML undergoing chemotherapy. Of particular interest is the capacity of some commensal bacteria to modulate the tumor microenvironment and response to chemotherapy. Moreover, increased mortality and reduced overall survival have been reported in patients who have undergone allogeneic stem cell transplantation and exhibit decreased gut microbiome diversity at the time of transplantation. These findings indicate that the composition of gut microbiota may play an important role in the prognosis of AML, especially in relation to therapeutic response. This narrative review summarizes new research into the role of the intestinal microbiome and the underlying alterations observed in patients with AML, resulting from the disease and therapeutic interventions and outlines strategies to improve its function and outcomes.
- 7 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3571
Open AccessThe Role of Gut Microbiota in Acute Myeloid Leukemia
Gut microbiota plays a crucial role in regulating immune system function and shaping immunological responses to pathogens capable of causing infections. Alterations in the composition of the intestinal microbiome are associated with immune system dysfunction and increased susceptibility to infections. Patients with acute myeloid leukemia (AML) are highly susceptible to infections due to immune system deregulation caused by the disease itself, as well as chemotherapy-induced bone marrow aplasia. In these patients, gut microbiota dysbiosis and reduced microbial diversity (i.e., imbalances in the composition and function of intestinal microbes) result from multiple factors, including the underlying disease, neutropenia, dietary factors, use of antibiotics, chemotherapy regimens and prolonged hospitalization. Chemotherapy, for instance, induces damage to the intestinal mucosa and disrupts the epithelial barrier, resulting in deregulation of the intestinal microbiome. Previous studies have reported alterations in the human intestinal microbiome in patients with AML undergoing chemotherapy. Of particular interest is the capacity of some commensal bacteria to modulate the tumor microenvironment and response to chemotherapy. Moreover, increased mortality and reduced overall survival have been reported in patients who have undergone allogeneic stem cell transplantation and exhibit decreased gut microbiome diversity at the time of transplantation. These findings indicate that the composition of gut microbiota may play an important role in the prognosis of AML, especially in relation to therapeutic response. This narrative review summarizes new research into the role of the intestinal microbiome and the underlying alterations observed in patients with AML, resulting from the disease and therapeutic interventions and outlines strategies to improve its function and outcomes.
- Open Access
Clonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation
Clonal hematopoiesis refers to the clonal expansion of hematopoietic stem and progenitor cells, driven by somatic mutations. Major mutated genes in clonal hematopoiesis include genes involved in epigenetic regulation including DNA methylation and/or chromatin modification (e.g., DNMT3A, TET2, and ASXL1), tumor suppressors (e.g., TP53), signal transduction (e.g., JAK2), and RNA splicing (e.g., SF3B1 and SRSF2). Clonal hematopoiesis includes clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of unknown significance (CCUS), and myelodysplastic syndromes/neoplasms (MDS). CHIP occurs when the frequency of the variant allele equals or exceeds 2% (4% for X-linked genes in males) in the absence of cytopenias. CHIP is common among older persons and is associated with an increased risk of hematologic cancer. CHIP is also associated with an increased risk of atherosclerotic disease including acute myocardial infarction, stroke, cardiac failure, and abdominal aneurysm. Increasing evidence suggests that CHIP is associated with venous thromboembolic disease. Somatic mutations lead to proliferation of hematopoietic progenitor cells and their progeny, resulting in excessive activation of granulocytes and monocytes. It could be postulated that chronic inflammation caused by clonal expansion of myeloid cells carrying mutations in DNMT3A, TET2, and ASXL1 (“DTA”) genes may constitute an independent risk factor in clot formation and endothelial-cell damage. DTA mutations correlate with elevated proinflammatory cytokines such as IL-1β and IL-6 and enhanced activation of inflammasomes. Moreover, JAK2 mutations may have a direct role in the activation of platelets and coagulation. In vivo murine studies have demonstrated that activation of the JAK-STAT signaling pathway promotes neutrophil extracellular trap (NET) formation, contributing to a prothrombotic state. Insights from related clonal disorders such as paroxysmal nocturnal hemoglobinuria and the VEXAS syndrome support the concept that mutation-driven innate immune activation can directly perturb hemostatic balance. This review aims to summarize the association between clonal expansion of hematopoietic cells and thrombotic disease, and highlight how somatic mutations in hematopoietic cells may contribute to vascular disease and thrombogenesis.
Open AccessClonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation
Clonal hematopoiesis refers to the clonal expansion of hematopoietic stem and progenitor cells, driven by somatic mutations. Major mutated genes in clonal hematopoiesis include genes involved in epigenetic regulation including DNA methylation and/or chromatin modification (e.g., DNMT3A, TET2, and ASXL1), tumor suppressors (e.g., TP53), signal transduction (e.g., JAK2), and RNA splicing (e.g., SF3B1 and SRSF2). Clonal hematopoiesis includes clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of unknown significance (CCUS), and myelodysplastic syndromes/neoplasms (MDS). CHIP occurs when the frequency of the variant allele equals or exceeds 2% (4% for X-linked genes in males) in the absence of cytopenias. CHIP is common among older persons and is associated with an increased risk of hematologic cancer. CHIP is also associated with an increased risk of atherosclerotic disease including acute myocardial infarction, stroke, cardiac failure, and abdominal aneurysm. Increasing evidence suggests that CHIP is associated with venous thromboembolic disease. Somatic mutations lead to proliferation of hematopoietic progenitor cells and their progeny, resulting in excessive activation of granulocytes and monocytes. It could be postulated that chronic inflammation caused by clonal expansion of myeloid cells carrying mutations in DNMT3A, TET2, and ASXL1 (“DTA”) genes may constitute an independent risk factor in clot formation and endothelial-cell damage. DTA mutations correlate with elevated proinflammatory cytokines such as IL-1β and IL-6 and enhanced activation of inflammasomes. Moreover, JAK2 mutations may have a direct role in the activation of platelets and coagulation. In vivo murine studies have demonstrated that activation of the JAK-STAT signaling pathway promotes neutrophil extracellular trap (NET) formation, contributing to a prothrombotic state. Insights from related clonal disorders such as paroxysmal nocturnal hemoglobinuria and the VEXAS syndrome support the concept that mutation-driven innate immune activation can directly perturb hemostatic balance. This review aims to summarize the association between clonal expansion of hematopoietic cells and thrombotic disease, and highlight how somatic mutations in hematopoietic cells may contribute to vascular disease and thrombogenesis.